Inhaled colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria: A real-life experience in tertiary care hospitals in Saudi Arabia

Abstract

Background Nosocomial pneumonia (NP) due to multidrug-resistant (MDR) Gram-negative pathogens, has continued to rise over the last several decades. Parenteral administration of colistin results in poor alveolar penetration and subtherapeutic concentration; therefore, direct drug deposition at site of infection may improve the effectiveness while minimizing the systemic exposure. The aim of this study is to describe the safety and effectiveness of inhaled colistin for the treatment of NP caused by MDR Gram-negative pathogens. Method Patients who received inhaled colistin from May 2015 to May 2019 at 2 different tertiary care hospitals in Riyadh, Saudi Arabia were identified from pharmacy databases and their charts were retrospectively reviewed. Results 86 patients were enrolled in this study. The mean age was 56 ± 20 years. The mean Acute Physiology and Chronic Health Evaluation (APACHE II) was 17 ± 5. The responsible pathogens for NP were Pseudomonas aeruginosa (60%) Acinetobacter baumannii (28%), and Klebsiella pneumoniae (9%). Most patients (76/86) received concomitant intravenous antibiotics. Mean colistin total daily dose was 6 ± 3 million international units divided into 2–3 doses. Mean inhaled colistin duration of therapy was 11 ± 6 days. Favorable clinical outcome was achieved in 51 (59%) patients while favorable microbiological outcome occurred in 29 (34%) patients. Death due to all causes was noted in 39 (45%) cases. Renal injury occurred in 19 (22%) patients, all received concomitant intravenous colistin. Conclusion Inhaled colistin can be considered as salvage therapy as adjunct to intravenous administration for treatment of patients with NP due to MDR Gram-negative pathogens.

Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic

“…This is especially important in regions where Gram-negative pathogens are resistant to carbapenems. We are aware that antimicrobials with less favorable safety profiles such as colistin, a ‘Reserve’ antibiotic, are recommended as empiric therapy for suspected Gram-negative infections [ 146 ]. This needs to be avoided in the future.…”

Impact of Positive Culture Reports of E. coli or MSSA on De-Escalation of Antibiotic Use in a Teaching Hospital in Pakistan and the Implications

“…1 In most cases, antibiotic-resistant pathogens are responsible for nosocomial infections, which have risen due to excessive use of broad-spectrum antibiotics. [2][3][4][5][6] This is a concern as the development of new antibiotics and repositioning of old antibiotics has slowed. 3,7 Alongside this, the Centers for Disease Control and Prevention (CDC) recognized that 20-50% of all antibiotics prescribed to patients in critical care hospitals in the US are either redundant or inappropriate.…”

Ongoing Strategies to Improve Antimicrobial Utilization in Hospitals across the Middle East and North Africa (MENA): Findings and Implications

“…It is recognized that this is a challenge for many MENA countries, particularly among those with a lower income. Countries are at different stages in their availability of data collection tools, and some still have extensive use of paper-based systems for data collection; however, there is an imperative need for NAPs for AMR to drive down AMR rates through improved antibiotic use [93][94][95][96]. Consequently, routine data collection, and the usefulness of collected data, is likely to change in order to reduce unnecessary prescribing [10,11,13].…”